BEYOND SYMPTOM CONTROL Developing therapies to help people with orphan conditions of the brain and nervous system live their lives to the fullest. Who We Are Noema Pharma is a biotech company developing groundbreaking therapies to address the most debilitating symptoms in orphan conditions of th ...
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Total raised: $173.56M
Founded date: 2020
Investors 4
| Date | Name | Website |
| 07.04.2021 | Sofinnova ... | sofinnovap... |
| 09.05.2023 | Jeito Capi... | jeito.life |
| - | Gilde Heal... | gildehealt... |
| - | Forbion | forbion.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.03.2023 | Series B | $112M | - |
| 20.12.2020 | Series A | $61.56M | - |
Mentions in press and media 22
| Date | Title | Description |
| 21.10.2024 | A new step in the clinical development | Based-based company NUCLIDIUM announced the imaging of the first patient in a Phase 1 clinical trial for its radiotracer, 61Cu-NuriPro™, aimed at diagnosing and staging prostate cancer. The phase 1 clinical trial aims at evaluating the com... |
| 15.08.2024 | Clinical advancements at ImmunOs Therapeutics and Noema Pharma | ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, has expanded its ongoing Phase I clinic... |
| 27.05.2024 | Biotechs record clinical trial successes | Noema Pharma, a clinical-stage biotech targeting debilitating neuroscience disorders, has treated the first patient in an open-label Phase 2a study (NOE-PPM-201) evaluating the safety and efficacy of NOE-115, a broad-spectrum monoamine mod... |
| 22.05.2024 | Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopa... | NOE-115 has the potential to benefit Vasomotor Symptoms (VMS) during menopause as well as associated clinical challenges including weight gain, daytime fatigue, and cognitive symptoms BASEL, Switzerland, May 22, 2024 – Noema Pharma AG, a cl... |
| 25.04.2024 | 10 Swiss startups to watch in 2024 | Although Switzerland's startup ecosystem might not be the largest in Europe, it is widely recognized as one of the most innovative. Both government and private initiatives play a crucial role in supporting Switzerland's startup scene, offer... |
| 07.08.2023 | European tech companies are leading the fight against debilitating and chronic pain | Did you know that chronic pain affects more than 1.5 billion people worldwide? Chronic and regular episodic pain can have profound and wide-ranging consequences, affecting everything from employment and education opportunities to relationsh... |
| 04.07.2023 | New executives to drive Life sciences and Fintech startups on the next journey | |
| 10.04.2023 | Il mercato del Venture Capital a marzo 2023 | Come è andato il mercato del Venture Capital a marzo 2023? Come sempre partiamo dai dati per poi passare ad alcune tra le startup, le scaleup e i round più interessanti. Il mese di marzo vede una leggera flessione della raccolta in Europa,... |
| 07.03.2023 | Swiss biotech company Noema Pharma secures €103M to advance CNS drug development | Basel, Switzerland-based Noema Pharma, a clinical-stage biotech company, announced on Tuesday that it has raised CHF 103M (approximately €103.5M) in an oversubscribed Series B round of funding co-led by European healthcare-focused investmen... |
| 07.03.2023 | Noema Pharma raises CHF103 million |
Show more